Sirna Therapeutics Announces Pricing of Common Stock Offering
May 24 2006 - 7:14AM
PR Newswire (US)
SAN FRANCISCO, May 24 /PRNewswire-FirstCall/ -- Sirna Therapeutics,
Inc. (NASDAQ:RNAI) announced today the pricing of an underwritten
public offering of 9,000,000 shares of its common stock at $5.00
per share. This offering was increased from the previously
announced offering size of 8,000,000 shares. All of the shares are
being offered by Sirna pursuant to an effective shelf registration
statement previously filed with the SEC. Sirna has granted a 30-day
option to the underwriters to purchase up to 1,350,000 additional
shares of common stock at the public offering price to cover
over-allotments, if any. UBS Investment Bank and J.P. Morgan
Securities Inc. are acting as joint bookrunning managers for the
offering. Co-managers for the offering are CIBC World Markets,
Leerink Swann & Company and Brean Murray, Carret & Co. A
copy of the prospectus supplement relating to the offering may be
obtained by contacting UBS Investment Bank, Prospectus Department,
299 Park Avenue, New York, New York 10171 (212-821-3000), or J.P.
Morgan Securities Inc., Prospectus Department, 4 Chase Metrotech
Center, CS Level, Brooklyn, New York 11245 (718-242-8002). This
communication shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any jurisdiction in which the offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of that jurisdiction. About
Sirna Therapeutics Sirna Therapeutics is a clinical-stage
biotechnology company developing RNAi-based therapies for serious
diseases and conditions, including age-related macular
degeneration, hepatitis B and C, dermatology, asthma, Huntington's
disease, diabetes, and respiratory syncytial virus. Safe Harbor
Statement Statements in this press release which are not strictly
historical, including with respect to Sirna's proposed public
offering, are "forward- looking" statements which should be
considered as subject to many risks and uncertainties. You should
consider the risk factors identified in the prospectus supplement
and the accompanying prospectus, and in Sirna's Securities and
Exchange Commission filings, including its Forms 10-K and 10-Q and
in other SEC filings. Sirna undertakes no obligation to revise or
update any forward-looking statements in order to reflect events or
circumstances that may arise after the date of this release.
Contacts: Greg Weaver, SVP and Chief Financial Officer, Sirna
Therapeutics, Inc., 415-512-7200 Rebecca Galler Robison, Senior
Director, Corporate Strategy, Sirna Therapeutics, Inc.,
303-449-6500 DATASOURCE: Sirna Therapeutics, Inc. CONTACT: Greg
Weaver, SVP and Chief Financial Officer, +1-415-512-7200, or
Rebecca Galler Robison, Senior Director, Corporate Strategy,
+1-303-449-6500, both of Sirna Therapeutics, Inc.
Copyright
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Apr 2024 to May 2024
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From May 2023 to May 2024